trending Market Intelligence /marketintelligence/en/news-insights/trending/bjIuaZ0JLBbQobGjB1DF0w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Genentech reports positive results from 2nd phase 3 trial of lung cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Genentech reports positive results from 2nd phase 3 trial of lung cancer drug

Genentech's second phase 3 trial for Alecensa showed that the drug significantly reduced the risk of disease worsening or death by 53% versus crizotinib when given as initial treatment for people with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.

Median progression-free survival reported by the investigators, the primary endpoint of the study, was not yet reached in people who received Alecensa versus 11.1 months in those who received crizotinib.

The secondary endpoint of median progression-free survival assessed by an independent review committee was 25.7 months for those who received Alecensa versus 10.4 months for people who received crizotinib.

Alecensa reduced the risk of disease progression in the central nervous system by 84%. The 12-month cumulative rate of central nervous system progression for people with or without existing central nervous system metastases at baseline was 9.4% for Alecensa and 41.4% for crizotinib.

Genentech will submit the results to global health authorities, including the U.S. Food and Drug Administration. In September 2016, The U.S. FDA granted the drug breakthrough therapy designation for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer in patients who have not received prior treatment with an anaplastic lymphoma kinase inhibitor.

Alecensa received accelerated approval from the U.S. FDA in December 2015 for the treatment of people with anaplastic lymphoma kinase-positive non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

Genentech is a part of Roche Holding Ltd.